Prescription for Conflict:
Should Industry Fund Continuing Medical Education?



Disclosures

Daniel Carlat, MD: Clearview Publishing (President); CME Newsletter (Dr. Carlat's lecture not included towards earning CME credit)

Glenn Demott, MS: No disclosures listed

Carl Elliott, MD, PhD: No disclosures listed

Michael Frisch, JD: No disclosures listed

Adriane Fugh-Berman, MD: Expert witness on behalf of plaintiffs in litigation regarding pharmaceutical marketing practices

Jeremy Greene, MD, PhD: No disclosures listed

Mark Helm, MD, MBA: Helm Benefit Design

Elissa Ladd, PhD, RN: No disclosures listed

Joel Lexchin, MD: No disclosures listed

Douglas Melnick, MD, MPH: Consulted for plaintiff's attorney in a case involving allegations of illegal marketing practices by a pharmaceutical company

Edmund Pellegrino, MD: No disclosures listed

Hanadi Shamkhani, MD, RPh: No disclosures listed

Joshua Sharfstein, MD: No disclosures listed

Julie Taitsman, JD, MD,: No disclosures listed

Paul Thacker: No disclosures listed

Stephen Willis, MD: No disclosures listed

Robert Wittes, MD: No disclosures listed


Note: Disclosures were not requested for Maureen Doyle-Scharff, MBA, FACME; Norman Kahn, MD; David Davis, MD; Mike Saxton, MEd; and Alicia Mundy because the Pros and Cons of Industry-Funded Education panel was not eligible for CME or CEU credit.



Return to top of page

Return to conference home page


Our Videos



Pharma Insider II
Opposition research
(read transcript)


Pharma Insider I
Off-label promotion under the radar
(read transcript)

The Art of Medical Writing
Pharma's anonymous writers

Drug Reps Talk Shop II
Drug reps continue their chat

Drug Reps Talk Shop I Selling drugs to docs

Director of PharmedOut Explains the Project

Zyprexa Drug Rep Tells All Shahram Ahari describes how he sold the drug
All content on this site is © 2006 by PharmedOut * (p) 202-687-1191 * (f) 202-687-7407 * Georgetown University
Department of Physiology and Biophysics * Box 571460 * Washington, DC 20057-1460